Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
SLAS Discov ; 24(2): 111-120, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30589598

RESUMEN

SLC6A19 (B0AT1) is a neutral amino acid transporter, the loss of function of which results in Hartnup disease. SLC6A19 is also believed to have an important role in amino acid homeostasis, diabetes, and weight control. A small-molecule inhibitor of human SLC6A19 (hSLC6A19) was identified using two functional cell-based assays: a fluorescence imaging plate reader (FLIPR) membrane potential (FMP) assay and a stable isotope-labeled neutral amino acid uptake assay. A diverse collection of 3440 pharmacologically active compounds from the Microsource Spectrum and Tocriscreen collections were tested at 10 µM in both assays using MDCK cells stably expressing hSLC6A19 and its obligatory subunit, TMEM27. Compounds that inhibited SLC6A19 activity in both assays were further confirmed for activity and selectivity and characterized for potency in functional assays against hSLC6A19 and related transporters. A single compound, cinromide, was found to robustly, selectively, and reproducibly inhibit SLC6A19 in all functional assays. Structurally related analogs of cinromide were tested to demonstrate structure-activity relationship (SAR). The assays described here are suitable for carrying out high-throughput screening campaigns to identify modulators of SLC6A19.


Asunto(s)
Sistemas de Transporte de Aminoácidos Neutros/antagonistas & inhibidores , Bioensayo/métodos , Sistemas de Transporte de Aminoácidos Neutros/metabolismo , Animales , Línea Celular , Fluorescencia , Humanos , Marcaje Isotópico , Potenciales de la Membrana , Xenopus laevis
2.
Sci Rep ; 8(1): 3681, 2018 02 27.
Artículo en Inglés | MEDLINE | ID: mdl-29487322

RESUMEN

Certain recessively inherited diseases result from an enzyme deficiency within lysosomes. In mucopolysaccharidoses (MPS), a defect in glycosaminoglycan (GAG) degradation leads to GAG accumulation followed by progressive organ and multiple system dysfunctions. Current methods of GAG analysis used to diagnose and monitor the diseases lack sensitivity and throughput. Here we report a LC-MS method with accurate metabolite mass analysis for identifying and quantifying biomarkers for MPS type I without the need for extensive sample preparation. The method revealed 225 LC-MS features that were >1000-fold enriched in urine, plasma and tissue extracts from untreated MPS I mice compared to MPS I mice treated with iduronidase to correct the disorder. Levels of several trisaccharides were elevated >10000-fold. To validate the clinical relevance of our method, we confirmed the presence of these biomarkers in urine, plasma and cerebrospinal fluid from MPS I patients and assessed changes in their levels after treatment.


Asunto(s)
Biomarcadores/sangre , Biomarcadores/orina , Mucopolisacaridosis I/sangre , Mucopolisacaridosis I/orina , Animales , Cromatografía Liquida , Modelos Animales de Enfermedad , Femenino , Glicosaminoglicanos/sangre , Heparitina Sulfato/sangre , Humanos , Iduronidasa/sangre , Masculino , Ratones , Trisacáridos/sangre
3.
Sci Rep ; 8(1): 4994, 2018 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-29556060

RESUMEN

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA